Fri.Nov 15, 2024

article thumbnail

Epionce Intense Recharge Mask Supercharges Skin Radiance With Next-Gen Botanicals

MedEsthetics

Supercharged with next-generation botanical extracts and proven barrier-rejuvenating ingredients, this mask enhances skin radiance for a visibly brighter, healthier complexion after just one use.

article thumbnail

Lip Filler vs. Lip Flip: Which Is Right for You?

AAFE - American Academy of Facial Esthetics

By Brigid Landrum, RN When it comes to enhancing your smile, the world of cosmetic procedures offers a variety of options to achieve your desired look. Two popular treatments that often come into play are lip fillers and lip flips. Both can help enhance the appearance of your lips, but they serve different purposes and are suitable for different needs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

What is "Ozempic Face" & Why Does it Occur? Separating Fact From Fiction

MedEsthetics

We're diving into the "Ozempic Face" phenomenon to examine Ozempic's various effects on facial skin, what causes these side effects and separating the myths from the truth about its impact on facial aesthetics.

Facials 78
article thumbnail

Hairdustry Hosts Fifth Annual Presley Poe and Friends Event With “Tech Behind the Chair” Theme

Beauty Launchpad

Hairdustry is excited to announce the fifth annual Presley Poe and Friends event, set for April 26-27, 2025, in Frederick, Maryland. This year’s theme, “Tech Behind the Chair,” will showcase the latest innovations driving the future of hairstyling.

article thumbnail

Multi-Mechanical Therapies with Topicals For Age Management

Lipgloss and Aftershave

Microneedling and nano infusion are powerful tools on their own, but together, they create a synergistic effect that can transform your clients’ skin. By incorporating one microneedling treatment every three months and supporting it with 3 – 4 nano infusion treatments in between, while using topicals with potent ingredients and a proven delivery system professionals provide a comprehensive treatment that delivers visible, long-lasting age management results.

article thumbnail

From Clinic to Industry: Insights Into the MSL Role and PA Advocacy

Dermatology Times

At the 2024 SDPA Fall Conference, Sara Wilchowski, DMSc, MPAS, PA-C, highlighted the challenges and rewards of transitioning to industry roles, the impact of “Insta-Tok” on patient care, and the evolving landscape of dermatology.

Clinic 41

More Trending

article thumbnail

Clascoterone Cream 1% Deemed Stable When Combined With Other Topical Acne Treatments

Dermatology Times

A poster presented at the 2024 SDPA Fall Conference demonstrated that clascoterone cream remains stable when paired with commonly prescribed acne topicals, supporting its role in multimodal therapy.

article thumbnail

FDA Accepts Dupilumab sBLA for CSU; New PDUFA Date Set

The Dermatology Digest

The U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental Biologics License Application (sBLA) for dupilumab (Dupixent, Sanofi & Regeneron) to treat adults and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) whose disease is not adequately controlled with H1 antihistamine treatment.

Safety 28
article thumbnail

Comparing the Efficacy of Roflumilast and Crisaborole

Dermatology Times

Panelists discuss how topical PDE4 inhibitors compare to traditional treatments like corticosteroids in terms of efficacy, safety, and long-term disease control, while also examining the unique formulations of roflumilast and crisaborole and their implications for skin penetration and patient experience; they highlight practical considerations for application, the management of adverse effects such as stinging and burning, and the distinct advantages of PDE4 inhibitors in addressing specific gap

article thumbnail

Roflumilast: Mechanism, and Use for Proactive AD Management

Dermatology Times

Panelists discuss common misconceptions about the mechanism of action of PDE4 inhibitors in clinical practice, emphasizing that not all PDE4 inhibitors are created equal and how these differences can significantly impact their efficacy and safety profiles.

article thumbnail

PDE4 Inhibitor Roflumilast for AD

Dermatology Times

Panelists discuss the current landscape of topical treatments for atopic dermatitis, focusing on the evolution of nonsteroidal options over the past decade, and explain the mechanism of action of PDE4 inhibitors in specifically targeting inflammatory pathways associated with the condition.

article thumbnail

Poster Highlights RFMN’s Promise for Treating Hypertrophic Scars in Darker Skin

Dermatology Times

Case studies demonstrate success with radiofrequency microneedling for hypertrophic scars in Fitzpatrick IV through VI.

article thumbnail

Day 2 Recap: SDPA Fall 2024

Dermatology Times

Catch up on coverage from the second day of the 2024 Society of Dermatology Physician Associates Fall Conference in Las Vegas, Nevada.

article thumbnail

Day 3 Recap: SDPA Fall 2024

Dermatology Times

Catch up on coverage from the third day of the 2024 Society of Dermatology Physician Associates Fall Conference in Las Vegas, Nevada.

article thumbnail

Derm PAs Look to Give Back: Volunteering at the Sun Bus

Dermatology Times

Dermatology physician associates via DPAF conduct skin checks at the Sun Bus during Fall Conference.

article thumbnail

Empowering Dermatology PAs Through Education and Career Support

Dermatology Times

Michael Rubio, PA-C, previews the transformative programming and career-focused initiatives at this year’s Society of Dermatology Physician Associates Fall Conference in Las Vegas.

article thumbnail

SDPA Opens 30th Anniversary Conference With New Initiatives, Membership Milestones, and Awards

Dermatology Times

SDPA President Amber Blair, PA-C, discusses new member opportunities and recognizes PA leaders.

41
article thumbnail

FDA Accepts sBLA of Dupilumab for the Treatment of Chronic Spontaneous Urticaria

Dermatology Times

The target action date for the FDA decision is April 18, 2025.